Evotec AG announced that CENTOGENE, the worldwide leader in elucidating rare disease genetics for patients, clinicians and pharmaceutical partners, and Evotec entered into a global strategic collaboration agreement for joint drug discovery projects, developing compounds to treat rare genetic diseases.
Evotec (Hamburg, Germany) and CENTOGENE initiated the collaboration to develop a strategic high-throughput platform for testing novel small molecules in rare hereditary metabolic diseases.
The collaboration brings together Evotec’s leading induced pluripotent stem cell platform and broad drug discovery capabilities with CENTOGENE’s unique medical and genetic insights. In particular, detailed genotype-phenotype data enables rapid biomarker development using patient primary cells.
Centogene AG is a laboratory that focuses on genetic and biochemical diagnostic testing services for rare hereditary disorders for the medical community in Germany and internationally. It supports clinicians with genetic counseling services and newborn screening, as well as performs analysis of biomarkers for lysosomal storage disorders.
Centogene was founded in 2006 and is based in Rostock (Germany) with a laboratory in Cambridge, Massachusetts (USA). It also has locations in Freiburg (Germany); Dubai (United Arab Emirates) and Noida (India).